ECSP19037610A - Comprimido compuesto oral que comprende ezetimiba y rosuvastatina - Google Patents
Comprimido compuesto oral que comprende ezetimiba y rosuvastatinaInfo
- Publication number
- ECSP19037610A ECSP19037610A ECSENADI201937610A ECDI201937610A ECSP19037610A EC SP19037610 A ECSP19037610 A EC SP19037610A EC SENADI201937610 A ECSENADI201937610 A EC SENADI201937610A EC DI201937610 A ECDI201937610 A EC DI201937610A EC SP19037610 A ECSP19037610 A EC SP19037610A
- Authority
- EC
- Ecuador
- Prior art keywords
- rosuvastatin
- diluent
- water
- ezetimibe
- ezetimiba
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan un comprimido compuesto oral y un método para prepararlo. El comprimido compuesto oral incluye: una porción de gránulos húmedos de ezetimiba que incluye ezetimiba; y una porción de mezcla de rosuvastatina que incluye rosuvastatina o una de sus sales farmacéuticamente aceptables, donde la porción de gránulos húmedos de ezetimiba incluye, a modo de aglutinante, povidona que tiene un peso molecular promedio ponderado de aproximadamente 30 000 a aproximadamente 50 000, y la porción de mezcla de rosuvastatina incluye un diluyente, que incluye un diluyente hidrosoluble y un diluyente no hidrosoluble, teniendo el diluyente no hidrosoluble un tamaño de partícula (d90) de aproximadamente 98 um a aproximadamente 229 um correspondiente a un 90% en una distribución de tamaños de partícula acumulativa de las partículas totales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160160513A KR102206535B1 (ko) | 2016-11-29 | 2016-11-29 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19037610A true ECSP19037610A (es) | 2019-06-30 |
Family
ID=62241643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201937610A ECSP19037610A (es) | 2016-11-29 | 2019-05-28 | Comprimido compuesto oral que comprende ezetimiba y rosuvastatina |
Country Status (8)
Country | Link |
---|---|
KR (1) | KR102206535B1 (es) |
BR (1) | BR112019010706A2 (es) |
CL (1) | CL2019001424A1 (es) |
EC (1) | ECSP19037610A (es) |
MX (1) | MX2019006148A (es) |
MY (1) | MY197281A (es) |
SG (1) | SG11201903261VA (es) |
WO (1) | WO2018101681A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021019499A1 (en) | 2019-07-31 | 2021-02-04 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Solid oral multiple-unit immediate release compositions, methods and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
DK2844233T3 (da) | 2012-05-01 | 2020-07-13 | Althera Life Sciences Llc | Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme |
KR20150079373A (ko) * | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
KR101977785B1 (ko) * | 2014-06-25 | 2019-05-14 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법 |
KR101834559B1 (ko) * | 2015-02-27 | 2018-03-06 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 고형 복합제제 |
-
2016
- 2016-11-29 KR KR1020160160513A patent/KR102206535B1/ko active IP Right Grant
-
2017
- 2017-11-24 MY MYPI2019002029A patent/MY197281A/en unknown
- 2017-11-24 SG SG11201903261VA patent/SG11201903261VA/en unknown
- 2017-11-24 BR BR112019010706A patent/BR112019010706A2/pt not_active IP Right Cessation
- 2017-11-24 WO PCT/KR2017/013508 patent/WO2018101681A1/en active Application Filing
- 2017-11-24 MX MX2019006148A patent/MX2019006148A/es unknown
-
2019
- 2019-05-27 CL CL2019001424A patent/CL2019001424A1/es unknown
- 2019-05-28 EC ECSENADI201937610A patent/ECSP19037610A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MY197281A (en) | 2023-06-09 |
KR20180060705A (ko) | 2018-06-07 |
WO2018101681A1 (en) | 2018-06-07 |
KR102206535B1 (ko) | 2021-01-22 |
SG11201903261VA (en) | 2019-05-30 |
CL2019001424A1 (es) | 2019-10-04 |
MX2019006148A (es) | 2019-08-14 |
BR112019010706A2 (pt) | 2019-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2016005236A (es) | Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina | |
WO2015160641A3 (en) | Compounds useful as immunomodulators | |
CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
TN2017000524A1 (en) | New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | |
TN2018000395A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
GEP20197003B (en) | Aminopyrimidinyl compounds as jak inhibitors | |
MA39883A (fr) | Particules inorganiques individualisées | |
PH12021550603A1 (en) | Compositions and methods of manufacturing protein microparticles | |
JOP20150154B1 (ar) | صيغة مادة مركبة للإعطاء عن طريق الفم تشتمل على إزيتمايب ورسيوفاستاتين وعملية تحضيرها | |
GEP20186910B (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
WO2016011049A3 (en) | Compositions and methods for disease treatment using nanoparticle delivered compounds | |
PH12016501841A1 (en) | Immunosuppressant formulation | |
AU2015316010A8 (en) | Crystalline forms of 6-( (6, 7-dimethoxyquinazolin-4-yl) oxy) -N,2-dimethylbenzofuran-3-carboxamide | |
PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
MX2018011799A (es) | Formas de dosificacion de liberacion prolongada disuasivas de abuso. | |
ECSP19037610A (es) | Comprimido compuesto oral que comprende ezetimiba y rosuvastatina | |
MX2017008983A (es) | Composición farmaceútica de sulfonamida. | |
WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
CL2018001842A1 (es) | Procedimiento para la preparación de gránulos | |
EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
GEP20197006B (en) | Pharmaceutical formulation of racecadotril | |
WO2015109154A3 (en) | Nanochannel compositions and methods | |
TH173378A (th) | "สูตรผสมคอมโพสิตสำหรับใช้ทางปากที่ประกอบรวมด้วยเอเซทิมิเบ และโรซูวาสทาทิน" | |
BR112017021111A2 (pt) | processo para fabricação de misturas de pós secos |